Sakakibara Shan Riku sold $561K of BLLN

Sakakibara Shan Riku (Chief Product Officer) sold 4,000 shares of BillionToOne, Inc. (BLLN) at $140.21 ($0.56M total) on 2026-07-31 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sakakibara Shan Riku
Published Aug 4, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:24 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLLN
Neutral
high confidence
Mentioned
$BLLN
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNNeutralLow
01

Why it matters

The newest fact is the specific open-market sale details (shares, price, total value) by the Chief Product Officer under a 10b5-1 plan.

02

Market read

Traders may note insider selling, but the 10b5-1 structure reduces the likelihood of a fundamental negative catalyst.

03

What to watch

The filing does not disclose reasons for sale, and the net size ($560.8k) may be small relative to company fundamentals, limiting tradable inference.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-04, transaction dated 2026-07-31

Background

The article is an SEC Form 4 insider transaction disclosure for BillionToOne, Inc.

Company-level read

Ticker impact

$BLLNNeutralHigh confidence
Context

BillionToOne Form 4 shows CPO Sakakibara Shan Riku sold 4,000 shares at $140.21 under a 10b5-1 plan.

Expected impact

Likely minimal near-term impact; any effect is more sentiment than fundamentals.

Evidence & confidence

The filing is an open-market sale by an officer under a pre-arranged 10b5-1 plan, with no accompanying operational or guidance change disclosed.

Market effects

No clear sector read-through; this is company-specific insider liquidity disclosure.

None indicated.

None indicated.

Counterpoint

Insider sales can be misread as bearish; a 10b5-1 plan often reflects scheduled diversification rather than negative expectations.

Key entities

  • BillionToOne, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Sakakibara Shan Riku

    Chief Product Officer who sold 4,000 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Why is BillionToOne stock sliding today?

BillionToOne stock fell 6.2% in pre-market trading after Fuzzy Panda Research disclosed a short position and alleged regulatory and billing misconduct, including overbilling and potential unlawful practices. The company's stock had already declined from its 52-week high of $150.44, and broader market pressures contributed to the decline.

$BLLNMed

BillionToOne shares slide in pre-market trading following short-seller report

BillionToOne (BLLN) shares fell 6% premarket after a short-seller report alleged improper billing, undisclosed regulatory scrutiny, and clinical claim weaknesses. Fuzzy Panda Research, which holds a short position, cited FOIA records, anonymous sources, and billing data. The report claims potential EBITDA reduction of 80% and False Claims Act penalties up to $1.2B. BillionToOne has not responded.

$BLLNMed

BillionToOne: Q3 Earnings Snapshot

BillionToOne (BLLN) reported Q3 earnings of $17.4M, or 32 cents per share, beating estimates of 16 cents. Revenue was $123M, exceeding forecasts of $116.2M. The company expects full-year revenue between $460M and $470M. Shares have risen 39% YTD.